Free Trial
NASDAQ:LRMR

Larimar Therapeutics (LRMR) Stock Price, News & Analysis

$7.99
-0.14 (-1.72%)
(As of 11:07 AM ET)
Today's Range
$7.82
$8.35
50-Day Range
$6.33
$9.89
52-Week Range
$2.18
$13.68
Volume
211,906 shs
Average Volume
538,130 shs
Market Capitalization
$509.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.33

Larimar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
162.4% Upside
$21.33 Price Target
Short Interest
Healthy
5.05% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.52mentions of Larimar Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.29) to ($2.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.83 out of 5 stars

Medical Sector

574th out of 892 stocks

Pharmaceutical Preparations Industry

269th out of 424 stocks

LRMR stock logo

About Larimar Therapeutics Stock (NASDAQ:LRMR)

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

LRMR Stock Price History

LRMR Stock News Headlines

Larimar Therapeutics (NASDAQ:LRMR) Trading 6.9% Higher
Alert: Your Bank is Dying – Act Now or Lose Everything!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Alert: Your Bank is Dying – Act Now or Lose Everything!
Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.
Larimar: Q1 Earnings Snapshot
LRMR Apr 2024 10.000 call
See More Headlines
Receive LRMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Larimar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/09/2024
Today
6/24/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LRMR
Fax
N/A
Employees
42
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.33
High Stock Price Target
$25.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+167.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-36,950,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.86 per share

Miscellaneous

Free Float
61,059,000
Market Cap
$509.76 million
Optionable
Optionable
Beta
0.88
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Dr. Carole S. Ben-Maimon M.D. (Age 65)
    CEO, President & Director
    Comp: $865k
  • Mr. Michael Celano CPA (Age 65)
    Secretary & CFO
    Comp: $577.58k
  • Dr. Gopi Shankar M.B.A. (Age 53)
    Ph.D., Chief Development Officer
    Comp: $593.02k
  • Mr. John Berman
    Vice President of Finance & Administration
  • Ms. Jennifer Spokes Johansson
    Vice President of Legal & Compliance
  • Dr. Russell G. Clayton Sr. (Age 63)
    D.O, D.O., Chief Medical Officer
  • Mr. Francis Michael Conway CPA
    VP & Controller

LRMR Stock Analysis - Frequently Asked Questions

Should I buy or sell Larimar Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Larimar Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" LRMR shares.
View LRMR analyst ratings
or view top-rated stocks.

What is Larimar Therapeutics' stock price target for 2024?

6 Wall Street analysts have issued 1-year price targets for Larimar Therapeutics' shares. Their LRMR share price targets range from $14.00 to $25.00. On average, they expect the company's share price to reach $21.33 in the next year. This suggests a possible upside of 162.4% from the stock's current price.
View analysts price targets for LRMR
or view top-rated stocks among Wall Street analysts.

How have LRMR shares performed in 2024?

Larimar Therapeutics' stock was trading at $4.55 at the beginning of 2024. Since then, LRMR shares have increased by 78.7% and is now trading at $8.13.
View the best growth stocks for 2024 here
.

Are investors shorting Larimar Therapeutics?

Larimar Therapeutics saw a decline in short interest in the month of May. As of May 31st, there was short interest totaling 3,220,000 shares, a decline of 17.6% from the May 15th total of 3,910,000 shares. Based on an average daily trading volume, of 515,900 shares, the days-to-cover ratio is currently 6.2 days.
View Larimar Therapeutics' Short Interest
.

When is Larimar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our LRMR earnings forecast
.

How were Larimar Therapeutics' earnings last quarter?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) announced its earnings results on Thursday, May, 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.03.

What ETF holds Larimar Therapeutics' stock?

iShares Neuroscience and Healthcare ETF holds 1,867 shares of LRMR stock, representing 0.51% of its portfolio.

Who are Larimar Therapeutics' major shareholders?

Larimar Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include RA Capital Management L.P. (9.48%), Janus Henderson Group PLC (6.30%), Vanguard Group Inc. (3.71%), StemPoint Capital LP (1.16%), Assenagon Asset Management S.A. (1.00%) and Ikarian Capital LLC (0.69%). Insiders that own company stock include Frank E Thomas, James E Flynn, Joseph Truitt, Michael Celano and Thomas Edward Hamilton.
View institutional ownership trends
.

How do I buy shares of Larimar Therapeutics?

Shares of LRMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LRMR) was last updated on 6/24/2024 by MarketBeat.com Staff

From Our Partners